These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 23969737)

  • 21. Progress in HIV vaccine development.
    Hsu DC; O'Connell RJ
    Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A critical question for HIV vaccine development: which antibodies to induce?
    Zolla-Pazner S
    Science; 2014 Jul; 345(6193):167-8. PubMed ID: 25013066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques.
    Dennis M; Eudailey J; Pollara J; McMillan AS; Cronin KD; Saha PT; Curtis AD; Hudgens MG; Fouda GG; Ferrari G; Alam M; Van Rompay KKA; De Paris K; Permar S; Shen X
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV Immunology Goes Out On a Limb.
    Doria-Rose NA; Mascola JR
    Immunity; 2016 May; 44(5):1088-90. PubMed ID: 27192575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New HIV Vaccine Approach Safely Stimulated Rare Precursors to Broadly Neutralizing Antibodies.
    Suran M
    JAMA; 2023 Feb; 329(7):527-528. PubMed ID: 36723948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
    Subbaraman H; Schanz M; Trkola A
    Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.
    Landais E; Moore PL
    Retrovirology; 2018 Sep; 15(1):61. PubMed ID: 30185183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost.
    Virnik K; Nesti E; Dail C; Scanlan A; Medvedev A; Vassell R; McGuire AT; Stamatatos L; Berkower I
    Vaccine; 2018 Aug; 36(34):5166-5172. PubMed ID: 30037665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.
    Geiß Y; Dietrich U
    AIDS Rev; 2015; 17(2):107-13. PubMed ID: 26035168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Translational research insights from completed HIV vaccine efficacy trials.
    Tieu HV; Rolland M; Hammer SM; Sobieszczyk ME
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2():S150-4. PubMed ID: 23764628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure.
    Kwong PD; Mascola JR
    Immunity; 2018 May; 48(5):855-871. PubMed ID: 29768174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.
    Koff WC
    Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress toward active or passive HIV-1 vaccination.
    Escolano A; Dosenovic P; Nussenzweig MC
    J Exp Med; 2017 Jan; 214(1):3-16. PubMed ID: 28003309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress in the rational design of an AIDS vaccine.
    Nabel GJ; Kwong PD; Mascola JR
    Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2759-65. PubMed ID: 21893538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The design and evaluation of HIV-1 vaccines.
    Saunders KO; Rudicell RS; Nabel GJ
    AIDS; 2012 Jun; 26(10):1293-302. PubMed ID: 22706011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteins mimicking epitope of HIV-1 virus neutralizing antibody induce virus-neutralizing sera in mice.
    Kosztyu P; Kuchar M; Cerny J; Barkocziova L; Maly M; Petrokova H; Czernekova L; Liskova V; Raskova Kafkova L; Knotigova P; Masek J; Turanek J; Maly P; Raska M
    EBioMedicine; 2019 Sep; 47():247-256. PubMed ID: 31544770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire.
    Parsons MS; Rouleau D; Routy JP; LeBlanc R; Grant MD; Bernard NF
    AIDS; 2011 Jun; 25(10):1249-64. PubMed ID: 21516028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.